KR20180000342A - 단백질-함유 제제의 안정화에 유용한 조성물 및 방법 - Google Patents

단백질-함유 제제의 안정화에 유용한 조성물 및 방법 Download PDF

Info

Publication number
KR20180000342A
KR20180000342A KR1020177036456A KR20177036456A KR20180000342A KR 20180000342 A KR20180000342 A KR 20180000342A KR 1020177036456 A KR1020177036456 A KR 1020177036456A KR 20177036456 A KR20177036456 A KR 20177036456A KR 20180000342 A KR20180000342 A KR 20180000342A
Authority
KR
South Korea
Prior art keywords
protein
antibody
acid
antibodies
ppm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177036456A
Other languages
English (en)
Korean (ko)
Inventor
준얀 지
준 리우
유창 존 왕
Original Assignee
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제넨테크, 인크. filed Critical 제넨테크, 인크.
Publication of KR20180000342A publication Critical patent/KR20180000342A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
KR1020177036456A 2010-03-22 2011-03-21 단백질-함유 제제의 안정화에 유용한 조성물 및 방법 Ceased KR20180000342A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31632610P 2010-03-22 2010-03-22
US61/316,326 2010-03-22
PCT/US2011/029206 WO2011119487A2 (en) 2010-03-22 2011-03-21 Compositions and methods useful for stabilizing protein-containing formulations

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020127024667A Division KR101878369B1 (ko) 2010-03-22 2011-03-21 단백질-함유 제제의 안정화에 유용한 조성물 및 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197025585A Division KR102218495B1 (ko) 2010-03-22 2011-03-21 단백질-함유 제제의 안정화에 유용한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20180000342A true KR20180000342A (ko) 2018-01-02

Family

ID=43977896

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197025585A Active KR102218495B1 (ko) 2010-03-22 2011-03-21 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
KR1020177036456A Ceased KR20180000342A (ko) 2010-03-22 2011-03-21 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
KR1020127024667A Active KR101878369B1 (ko) 2010-03-22 2011-03-21 단백질-함유 제제의 안정화에 유용한 조성물 및 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020197025585A Active KR102218495B1 (ko) 2010-03-22 2011-03-21 단백질-함유 제제의 안정화에 유용한 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020127024667A Active KR101878369B1 (ko) 2010-03-22 2011-03-21 단백질-함유 제제의 안정화에 유용한 조성물 및 방법

Country Status (15)

Country Link
US (3) US9662395B2 (enExample)
EP (2) EP2550018B1 (enExample)
JP (3) JP5937059B2 (enExample)
KR (3) KR102218495B1 (enExample)
CN (3) CN103124564B (enExample)
BR (1) BR112012021873B8 (enExample)
CA (2) CA2792125C (enExample)
ES (1) ES2722201T3 (enExample)
HR (1) HRP20190751T1 (enExample)
MX (1) MX354867B (enExample)
PL (1) PL2550018T3 (enExample)
RU (1) RU2584232C2 (enExample)
SI (1) SI2550018T1 (enExample)
TR (1) TR201905081T4 (enExample)
WO (1) WO2011119487A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2550018T3 (pl) 2010-03-22 2019-08-30 F.Hoffmann-La Roche Ag Kompozycje i sposoby użyteczne do stabilizowania preparatów zawierających białko
CN116077644A (zh) * 2011-10-31 2023-05-09 弗·哈夫曼-拉罗切有限公司 抗体制剂
HUE068207T2 (hu) * 2013-11-21 2024-12-28 Genmab As Antitest-drog konjugátumkészítmény
ES2910443T3 (es) * 2014-04-16 2022-05-12 Biocon Ltd Formulaciones de proteínas estables que comprenden un exceso molar de sorbitol
IS3008B (is) 2014-05-14 2018-12-15 Calor ehf Stöðgandi lausnir fyrir prótín og peptíð
EP2946765B1 (en) 2014-05-23 2016-08-31 Ares Trading S.A. Liquid pharmaceutical composition
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
EP3053572A1 (en) * 2015-02-06 2016-08-10 Ares Trading S.A. Liquid pharmaceutical composition
KR20180101479A (ko) * 2016-01-13 2018-09-12 젠맵 에이/에스 항체 및 그의 약물 접합체를 위한 제제
CN106771244B (zh) * 2016-12-28 2018-02-02 广州华弘生物科技有限公司 一种纤维蛋白原定量检测试剂盒及检测方法
CN106771148B (zh) * 2016-12-28 2018-03-06 广州华弘生物科技有限公司 一种免疫球蛋白m检测试剂盒及检测方法
TWI841554B (zh) 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
EP3745129A4 (en) * 2018-03-23 2021-03-24 Konica Minolta, Inc. MARKED ANTIBODY DISPERSION LIQUID AND KIT FOR SPFS
SG11202010993VA (en) 2018-05-07 2020-12-30 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
TWI844571B (zh) 2018-10-30 2024-06-11 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
CN113660953A (zh) * 2019-04-01 2021-11-16 豪夫迈·罗氏有限公司 用于稳定含蛋白质制剂的组合物和方法
US11513602B2 (en) 2019-09-10 2022-11-29 Wagner Spray Tech Corporation Gesture control of a fluid application system
CN111964942A (zh) * 2020-08-28 2020-11-20 湖南海尚仪器设备有限公司 基于工业环境污染物检测的采样方法
KR20230109655A (ko) * 2020-11-16 2023-07-20 더블유.엘. 고어 앤드 어소시에이트스, 인코포레이티드 흐림점이 없는 사전 충전 다회 투여 주입 디바이스, 방법 및 제형
CN112816684B (zh) * 2021-01-07 2024-08-30 武汉华美生物工程有限公司 血清淀粉样蛋白a的校准品稀释液、其制备方法及其应用
CA3236891A1 (en) * 2021-12-20 2023-06-29 Boehringer Ingelheim International Gmbh Method for determining the degree of oxidative degradation of polysorbate 20 in aqueous formulations
WO2025194043A1 (en) * 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB845274A (en) * 1955-10-06 1960-08-17 Gen Foods Corp Improved gelatin composition
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
EP0040409B1 (de) 1980-05-21 1984-11-14 Siemens Aktiengesellschaft Mosaiktafel mit geschlossener Frontseite
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU3722984A (en) * 1984-01-05 1985-07-11 Manlab Pty. Ltd. Reagents for immunoassay at elevated temperatures
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
CH671155A5 (enExample) 1986-08-18 1989-08-15 Clinical Technologies Ass
US5183746A (en) 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
JPS6475433A (en) * 1987-09-16 1989-03-22 Teijin Ltd Remedy for herpes simplex virus infection
ES2051830T3 (es) * 1987-11-27 1994-07-01 Akzo Nv Solucion acuosa estable de anticuerpos.
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
EP0420937B1 (en) 1988-06-21 1994-11-09 Genentech, Inc. Therapeutic compositions for the treatment of myocardial infarction
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
AU2309692A (en) * 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
ES2296839T3 (es) 1991-08-14 2008-05-01 Genentech Inc. Variantes de inmunoglobulinas para receptores fc-epsilon especificos.
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
AU687755B2 (en) 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK0674506T3 (da) 1992-12-02 2001-01-08 Alkermes Inc Væksthormonholdige mikrosfærer med styret frigivelse
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DK0733207T3 (da) 1993-12-10 1998-04-20 Genentech Inc Fremgangsmåder til diagnose af allergi og screening af anti-allergi-terapeutika
MX9602818A (es) 1994-01-18 1997-06-28 Genentech Inc Un metodo de tratamiento de infeccion parasitaria usando antagonistas ige.
MX9603773A (es) 1994-03-03 1997-07-31 Genentech Inc Anticuerpos monoclonales anti-interleucina-8 para el tratamiento de trastornos inflamatorios.
DK0779806T3 (da) 1994-09-09 2000-11-27 Takeda Chemical Industries Ltd Præparat til forsinket frigivelse indeholdende et metalsalt af et peptid
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CN1102854C (zh) 1995-06-07 2003-03-12 阿尔克姆斯控制治疗公司 人生长激素的延续释放组合物
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
CA2242414C (en) 1996-01-23 2012-01-03 Genentech, Inc. Anti-cd18 antibodies for use against stroke
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
DE69729209T2 (de) 1996-11-27 2005-05-19 Genentech, Inc., South San Francisco Humanisierte anti-koerper gegen cd11a
ATE293640T1 (de) 1997-04-07 2005-05-15 Genentech Inc Anti-vegf antikörper
PT981618E (pt) 1997-05-15 2007-11-23 Genentech Inc ''anticorpo anti-apo-2''
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
WO2001000245A2 (en) 1999-06-25 2001-01-04 Genentech, Inc. HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
WO2001023001A2 (en) * 1999-09-29 2001-04-05 The Trustees Of The University Of Pennsylvania Rapid peg-modification
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
NZ518477A (en) 1999-10-29 2004-10-29 Genentech Inc Isolated anti-prostate stem cell antigen (PSCA) antibodies that internalise upon binding to PSCA on a mammalian cell, including a PSCA-expressing tumour cell, in vivo
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
EP1324776B2 (en) 2000-10-12 2018-03-21 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
AU2002351495A1 (en) 2001-10-17 2003-04-28 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CN101914158A (zh) 2002-02-14 2010-12-15 免疫医疗公司 抗cd 20抗体及其融合蛋白和使用方法
CN103709250B (zh) 2002-10-17 2016-08-10 根马布股份公司 抗cd20的人单克隆抗体
EP1944320A1 (en) 2002-12-16 2008-07-16 Genentech, Inc. Immunoglobulin variants and uses thereof
JP4869064B2 (ja) * 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
EP1626993B1 (en) 2003-05-09 2015-03-11 Duke University Cd20-specific antibodies and methods of employing same
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
US9044381B2 (en) * 2003-06-24 2015-06-02 Baxter International Inc. Method for delivering drugs to the brain
EP1651663B1 (en) 2003-08-08 2017-05-17 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DK2135881T3 (da) 2005-06-20 2011-12-05 Genentech Inc Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor
NZ564843A (en) * 2005-08-03 2012-05-25 Immunogen Inc Immunoconjugate formulations comprising an immunoconjugate and an excipient in a buffered aqueous solution
ZA200800146B (en) * 2005-08-03 2009-10-28 Immunogen Inc Immunoconjugate formulations
NZ601913A (en) * 2008-01-15 2014-02-28 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
JP5705115B2 (ja) * 2008-09-10 2015-04-22 ジェネンテック， インコーポレイテッド 蛋白質の酸化的分解の予防のための組成物および方法
BRPI1006519A2 (pt) 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
PL2550018T3 (pl) * 2010-03-22 2019-08-30 F.Hoffmann-La Roche Ag Kompozycje i sposoby użyteczne do stabilizowania preparatów zawierających białko
JP2014522843A (ja) * 2011-06-30 2014-09-08 ジェネンテック， インコーポレイテッド 抗ｃ−ｍｅｔ抗体製剤
US9813410B2 (en) 2014-06-26 2017-11-07 Rakuten, Inc. Information processing apparatus, information processing method, and information processing program

Also Published As

Publication number Publication date
CA3027749A1 (en) 2011-09-29
WO2011119487A3 (en) 2013-05-10
JP2019048831A (ja) 2019-03-28
RU2012144626A (ru) 2014-04-27
JP5937059B2 (ja) 2016-06-22
JP6742805B2 (ja) 2020-08-19
WO2011119487A2 (en) 2011-09-29
JP2013527832A (ja) 2013-07-04
MX354867B (es) 2018-03-23
CA2792125A1 (en) 2011-09-29
RU2584232C2 (ru) 2016-05-20
BR112012021873B1 (pt) 2021-05-11
EP2550018B1 (en) 2019-02-27
JP6791929B2 (ja) 2020-11-25
US20130078232A1 (en) 2013-03-28
CA2792125C (en) 2019-02-12
EP2550018A1 (en) 2013-01-30
KR102218495B1 (ko) 2021-02-19
KR101878369B1 (ko) 2018-07-16
CN104998269B (zh) 2019-06-11
CN106983862A (zh) 2017-07-28
US20170224820A1 (en) 2017-08-10
JP2016193909A (ja) 2016-11-17
KR20190104254A (ko) 2019-09-06
PL2550018T3 (pl) 2019-08-30
CN103124564B (zh) 2016-11-09
BR112012021873A2 (pt) 2016-05-24
US20200023063A1 (en) 2020-01-23
CN104998269A (zh) 2015-10-28
CN103124564A (zh) 2013-05-29
MX2012010612A (es) 2012-10-03
EP3513810A1 (en) 2019-07-24
TR201905081T4 (tr) 2019-05-21
BR112012021873B8 (pt) 2021-09-14
SI2550018T1 (sl) 2019-05-31
ES2722201T3 (es) 2019-08-08
HRP20190751T1 (hr) 2019-06-14
KR20130010466A (ko) 2013-01-28
HK1216842A1 (zh) 2016-12-09
US9662395B2 (en) 2017-05-30

Similar Documents

Publication Publication Date Title
KR101878369B1 (ko) 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
US11938189B2 (en) Compositions and methods for stabilizing protein-containing formulations
RU2575830C2 (ru) Композиции и способы, включающие алкилгликозиды, для стабилизации содержащих белки составов
HK1216842B (zh) 对於稳定含有蛋白质的制剂有用的组合物和方法
HK1242962A1 (en) Compositions and methods useful for stabilizing protein-containing formulations
HK1184379B (en) Compositions and methods containing alkylgycosides for stabilizing protein- containing formulations

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20171218

Application number text: 1020127024667

Filing date: 20120921

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20171228

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180309

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190125

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180309

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190125

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20180910

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20190603

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190429

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20190125

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180910

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20180309